Compare Quest Diagnostics Inc (DGX) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Lithium Americas Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Lithium Americas Corp trades at $2.35 (market cap $850.38M). The key difference: Quest Diagnostics Inc is far larger — about 30× Lithium Americas Corp's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Lithium Americas Corp for 27 Days on average.
| DGX | LAC | |
|---|---|---|
Market Cap | $25.48B | $850.38M |
Volume | 941,866 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $10.05 |
52-Week Low | $173.49 | $2.36 |
Typical Hold Time | 56 Days | 27 Days |
Enterprise Value | $31.23B | $1.19B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
